European Lyme vaccine development summary

• Preclinical

  • Overall, protective immunity has been demonstrated against 6 of the 7 serotypes of pathogenic Borrelia.
  • Protection demonstrated against isolates from various countries

• Clinical

  • 90 µg candidate vaccine is safe and well tolerated
  • All three OspA are equally immunogenic
  • No immune interference between the three OspA

--> Next step: efficacy trial

Previous slide

Next slide

Back to first slide

View graphic version